Investing.com - Leerink Partners has assumed coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Outperform rating and a price target of $12.00, representing significant upside from the current ...
The latest update is out from Larimar Therapeutics ( (LRMR)). On December 16, 2025, Larimar Therapeutics executed an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, ...
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ...
Get the detailed quarterly/annual income statement for Larimar Therapeutics, Inc. (LRMR). Find out the revenue, expenses and profit or loss over the last fiscal year.
Richmond American Homes of Arizona, Inc., a subsidiary of Sekisui House U.S., Inc., is pleased to announce the Grand Opening ...
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) said members of its management team will present and hold one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference ...
Visit a quote page and your recently viewed tickers will be displayed here.
Latest SEC filings for Larimar Therapeutics, Inc. (LRMR).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback